KalVista Pharmaceuticals (NASDAQ:KALV) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a report issued on Monday morning, Benzinga reports.

A number of other equities analysts also recently issued reports on the company. Needham & Company LLC restated a buy rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday. HC Wainwright reissued a buy rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $11.87 on Monday. The firm has a market cap of $513.02 million, a price-to-earnings ratio of -3.49 and a beta of 0.89. The business has a 50-day simple moving average of $13.17 and a two-hundred day simple moving average of $12.40. KalVista Pharmaceuticals has a fifty-two week low of $7.21 and a fifty-two week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.04. As a group, research analysts predict that KalVista Pharmaceuticals will post -3.57 earnings per share for the current year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Christopher Yea sold 7,102 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $85,295.02. Following the completion of the sale, the insider now owns 84,467 shares of the company’s stock, valued at $1,014,448.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Paul K. Audhya sold 2,135 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the sale, the insider now directly owns 83,745 shares in the company, valued at approximately $1,038,438. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Yea sold 7,102 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total value of $85,295.02. Following the completion of the transaction, the insider now directly owns 84,467 shares in the company, valued at $1,014,448.67. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,452 shares of company stock valued at $282,491. 12.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KALV. nVerses Capital LLC purchased a new position in KalVista Pharmaceuticals during the second quarter worth $25,000. EntryPoint Capital LLC bought a new position in shares of KalVista Pharmaceuticals during the 1st quarter worth approximately $92,000. China Universal Asset Management Co. Ltd. lifted its position in KalVista Pharmaceuticals by 101.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock valued at $95,000 after acquiring an additional 4,043 shares during the last quarter. Entropy Technologies LP purchased a new position in KalVista Pharmaceuticals in the first quarter worth $121,000. Finally, PEAK6 Investments LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 1st quarter valued at $178,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.